ストックスクリーナーアプリを入手
429.82
1.13%
4.82
アフターアワーズ：
429.76
-0.06
-0.01%
前日終値:
$425.00
開ける：
$422.37
24時間の取引高:
953.13K
Relative Volume:
0.70
時価総額：
$109.09B
収益：
$12.34B
当期純損益:
$4.34B
株価収益率:
25.48
EPS:
16.8685
ネットキャッシュフロー:
$3.71B
1週間 パフォーマンス:
+1.39%
1か月 パフォーマンス:
-3.18%
6か月 パフォーマンス:
+4.97%
1年 パフォーマンス:
+0.05%
1日の値動き範囲:
$421.11
$431.94
1週間の範囲:
$412.27
$433.94
52週間の値動き範囲:
$362.50
$507.92
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | アップグレード | Maxim Group | Hold → Buy |
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-03-10 | 繰り返されました | Oppenheimer | Outperform |
| 2026-02-13 | アップグレード | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Investors heavily search Vertex Pharmaceuticals Incorporated (VRTX): Here is what you need to know - MSN
Biotech Stocks To Watch NowMay 9th - MarketBeat
Vertex Pharma stock (US92532F1003): Q1 2026 earnings beat lifts shares on growth in new disease area - AD HOC NEWS
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharma stock (US92532F1003): Mixed Q1 results and 2026 guidance reiterated - AD HOC NEWS
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Secures Reimbursement Agreement fo - GuruFocus
April 2026 — CDMO Opportunities And Threats Report - Bioprocess Online
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Vertex Pharmaceuticals Stock Analysis: 1991 IPO Growth and 2026 OutlookNews and Statistics - IndexBox
Vertex (VRTX) Q1 2026 Earnings Call Transcript - AOL.com
Vertex Pharmaceuticals (NASDAQ: VRTX) affiliate proposes stock sales; insider sales listed - Stock Titan
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy (VRTX) - Seeking Alpha
Michel Lagarde At Vertex Pharmaceuticals Acquires Stock Options Worth $9K - Benzinga
BRUCE SACHS Backs Up Beliefs With A Notable Acquisition Of Vertex Pharmaceuticals Stock Options Worth $9K - Benzinga
Vertex Pharmaceuticals Posts Mixed Q1; Investors Focus On Non-CF Pipeline For Growth - Sahm
German reimbursement deal for Vertex’ Casgevy - The Pharma Letter
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Vertex Pharmaceuticals (VRTX) and Sotera Health (SHC) - The Globe and Mail
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany - BioSpace
Vertex secures German reimbursement deal for gene therapy By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and Merck & Company (MRK) - The Globe and Mail
Is It Too Late To Consider Vertex Pharmaceuticals (VRTX) After Recent Share Price Weakness - Yahoo Finance
Vertex Pharmaceuticals: Investment Returns and Future Outlook - Intellectia AI
Is This Millionaire-Maker Biotech Stock a Buy Right Now? - The Motley Fool
Is This Millionaire-Maker Biotech Stock a Buy Right Now? - The Motley Fool
Vertex Pharmaceuticals Incorporated 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VRTX) 2026-05-06 - Seeking Alpha
Insider Sell: Sangeeta Bhatia Sells Shares of Vertex Pharmaceuti - GuruFocus
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q) - marketscreener.com
Vertex (VRTX) director receives options, defers vested shares into stock units - Stock Titan
Vertex (NASDAQ: VRTX) director receives new equity grants - Stock Titan
Vertex director Sangeeta Bhatia sells $134,746 of company stock By Investing.com - Investing.com South Africa
Vertex Pharmaceuticals Insider Sold Shares Worth $469,222, According to a Recent SEC Filing - marketscreener.com
Director Schneider shifts 796 Vertex (VRTX) shares into deferred units - Stock Titan
Vertex Pharmaceuticals EVP Joy Liu sells $469,222 in shares By Investing.com - Investing.com Nigeria
Vertex Pharmaceuticals EVP Joy Liu sells $469,222 in shares - Investing.com
Director at Vertex (NASDAQ: VRTX) receives 2,866 fully vested options - Stock Titan
Vertex (VRTX) director reports stock grant and 796-share deferral - Stock Titan
Vertex EVP Joy Liu (NASDAQ: VRTX) sells 1,104 shares in planned trade - Stock Titan
Vertex director Sangeeta Bhatia sells $134,746 of company stock - Investing.com
Vertex (VRTX) director gets 2,866 fully vested stock options grant - Stock Titan
Vertex (VRTX) director Alan Garber granted RSUs and fully vested options - Stock Titan
Lloyd Carney of Vertex (VRTX) receives fully vested options grant - Stock Titan
Vertex (VRTX) director granted 943 RSUs and sells 318 shares - Stock Titan
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex (NASDAQ: VRTX) Q1 profit climbs to $1.03B on $3.0B sales - Stock Titan
Vertex Pharmaceuticals Confident in Emerging Renal Franchise, Oppenheimer Says - Moomoo
VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth - sharewise.com
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings - Benzinga
Narrow-Moat Vertex's Strong Cash Flows From CF Franchise Support Portfolio Diversification - Morningstar
Vertex Dips On Mixed First-Quarter Report; But There's A Silver Lining - Investor's Business Daily
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
Vertex Pharmaceuticals Inc (VRTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Liu Joy | EVP and Chief Legal Officer |
May 01 '26 |
Sale |
425.02 |
1,104 |
469,222 |
20,729 |
| Bhatia Sangeeta N. | Director |
May 04 '26 |
Sale |
423.73 |
318 |
134,746 |
4,924 |
0.82%
0.65%
大文字化:
|
ボリューム (24 時間):